DYSPNOEA is the #2 most commonly reported adverse reaction for MEPOLIZUMAB, manufactured by GlaxoSmithKline LLC. There are 10,201 FDA adverse event reports linking MEPOLIZUMAB to DYSPNOEA. This represents approximately 5.9% of all 173,706 adverse event reports for this drug.
Patients taking MEPOLIZUMAB who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
DYSPNOEA10,201 of 173,706 reports
DYSPNOEA is moderately reported among MEPOLIZUMAB users, representing a notable but not dominant share of adverse events.
Other Side Effects of MEPOLIZUMAB
In addition to dyspnoea, the following adverse reactions have been reported for MEPOLIZUMAB:
DYSPNOEA has been reported as an adverse event in 10,201 FDA reports for MEPOLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is DYSPNOEA with MEPOLIZUMAB?
DYSPNOEA accounts for approximately 5.9% of all adverse event reports for MEPOLIZUMAB, making it one of the most commonly reported side effect.
What should I do if I experience DYSPNOEA while taking MEPOLIZUMAB?
If you experience dyspnoea while taking MEPOLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.